| 11th week of 2016 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20160074275 | Constant hot temperature flat massage ball - The constant hot temperature flat massage ball comprises one top shell-shaped receptacle, one bottom shell-shaped receptacle and a central heating unit which is either a hot water bag, which has circulating water tube, a water pump and a precision temperature control hot water reservoir equipped with a thermostat, or an electric heating pad, which has an electric cord and a thermostat. The top shell-shaped receptacle has a central recess to store the heating unit and a circular female threaded wall at the upper portion of central recess. The bottom shell-shaped receptacle also has a central recess to store the heating unit, a circular male threaded embankment above the central recess to screw into the above-mentioned circular female threaded wall and a groove which is built transversely across its wall and the above-mentioned male threaded embankment to admit the above mentioned circulating water tube and electric cord. The water bag of the above-mentioned central heating unit is heated by hot water, which is pre-heated to 100 to 104 degree Fahrenheit controlled by a thermostat in precision temperature hot water reservoir, through the circulating water tube pumped by a water pump. The central electric heating pad has a thermostat which is preferably adjusted at 100 to 104 degree Fahrenheit. The constant hot temperature flat massage ball is constantly heated by hat water bag or heating pad. Therefore, it can be used for continuously massage with massage body cream or lotion without interruption. | 2016-03-17 |
| 20160074277 | System and Method for Titrating In Vivo Cellular Reaction and Gene Expression Using Varying Oscillation Frequencies - A system and method for directing vibrational oscillating sonic waves toward a target tissue in the body of a person, to thereby influence a phenotypic differentiation of the target tissue at a cellular level, requires the use of an epidermal or implantable patch. Mounted on the patch is a sonic generator for generating sonic energy that entrains cellular functions of the target tissue for a desired phenotypic response. Also included is a unit for titrating the target tissue to monitor for changes in an expression level of the target tissue resulting from phenotypic differentiation. | 2016-03-17 |
| 20160074279 | MOTION STYLE ACUPUNCTURE TREATMENT METHOD FOR RELIEVING ACUTE LOW BACK PAIN - Disclosed is a motion style treatment (MST) technique, more particularly, a method for treatment of diseases using MST technique that includes applying acupuncture to meridians (or acupuncture points) at applied sites of the body of a patient, instructing the patient to move and conduct muscle motion of the above sites while applying acupuncture thereon, which in turn maximizes circulation of bio-energy on the applied sites, and activating stimulation of muscles, ligaments and/or nerves by acupuncture needles to maximize effects of acupuncture stimulation, thereby curing a patient suffering from acute low back pain with serious disability. | 2016-03-17 |
| 20160074280 | Closure Locking Assembly - A locking assembly for a closure system having a first vertical member configured to extend downward along a sidewall of a closure and including a first hook element and a second hook element. A second vertical member having a first hook element and a second hook element is configured to be connected to the first vertical member such that the second vertical member extends downward along an opposite side of the sidewall of the closure from the first vertical member. When the locking assembly is installed on the closure system in a locked position, the first and second vertical members are dimensioned and configured so that the first hook elements are disposed above opposing sides of a top surface of the closure and the second hook elements are disposed beneath opposing sides of the sidewall of the closure for preventing the closure from being removed from the container. | 2016-03-17 |
| 20160074281 | STERILE MEDICATION IDENTIFICATION AND LABELING SYSTEM - A method and apparatus for sterile labeling of medications and medical solutions including those in a first container having a sterile interior and a non-sterile exterior, the first container being received in a second container or membrane, at least one sterile printed label containing information specific to the medication or solution, provided in a third container having a sterile interior and a non-sterile exterior, the third container being removably affixed to the second container while maintaining association of the printed label to the contents of the first container. The medication or solution in the first container may be dispensed into a sterile container in the sterile field and one of the at least one sterile printed labels from the third container may be applied to the corresponding sterile container or medical accessory in the sterile field. The apparatus can further include packaging in which the first container is packaged. | 2016-03-17 |
| 20160074282 | COMPOUNDING DISPENSING GUN - A compounding dispensing gun includes a pawl-spring assembly and a hand-housing assembly. The hand-housing assembly is coupled to the pawl-spring assembly. The hand-housing assembly has a handle. A plunger assembly extends through the hand-housing assembly and includes a push rod and a push rod head removably coupled to the push rod. The push rod has a plurality of first notches and a plurality of second notches formed thereon. The push rod selectively cooperates with the pawl-spring assembly to advance the push rod and the push rod head during a dispensing operation. | 2016-03-17 |
| 20160074283 | Apparatus And Associated Methods For Tracking And Increasing Medication Adherence For Patients - A medication container comprises a body portion and a grid coupled to the body portion. The grid and the tray each comprise a corresponding number of wells configured to contain medication. The tray is configured to be inserted into and removed from the body portion, above the grid. The tray may be configured to be connected to and disconnected from the grid, when the tray is inserted into the body portion. The wells of the grid may be configured to be manually loaded with medication by a user and the wells of the tray may be configured to be received by the user loaded with medication in accordance with a medication regimen. The first wells may be integral with the grid and the second wells may be integral with the tray. | 2016-03-17 |
| 20160074284 | ASSISTED MEDICATION FILLING AND MANAGEMENT - A medication filling and management system comprises a medication storage device for assisting patients in filling and managing medication supplies. The medication storage device includes a number of electronically monitored storage compartments and a communication system to identify a medication to be provided from an adjacent medication commercial package, automatically identify to a user which compartments of the storage device are to be filled with the identified medication from the commercial package, and detect and communicate the filling and dispensing of the medication from the storage device. | 2016-03-17 |
| 20160074285 | TUBE MANAGEMENT SYSTEM - A tube management system has a tube receiving element, a base element, and attachment elements extending from the base element. The tube receiving element is provided with a gripping element that functions to prevent tube migration. The attachment elements are provided within openings for receiving a device which is used to secure the tube management system to a patient. | 2016-03-17 |
| 20160074286 | Cooling Pacifier - The invention provides for an infant pacifier that is configured to sooth an infant's discomfort during teething where the pacifier is filled with a freezable liquid or gel that stays cool over a prolonged period of time. The pacifier comprises a sucking portion, a shield portion, a handling means and a hollow cavity, the hollow cavity being formed in the sucking portion of the pacifier and filled with the liquid or gel through an opening in the shield portion, the opening having a plugging device to allow refilling of the liquid or gel. | 2016-03-17 |
| 20160074287 | INFANT MEDICINE FEEDER - An infant medicine feeder, including a pacifier, a protection plate, a connection disk, and a syringe. The protection plate is connected to the tail of the pacifier. The protection plate is connected to the syringe. The protection plate includes two rectangle holes, and one end of each of the rectangle holes is provided with a step. The pacifier, the protection plate, the connection disk, and the syringe are connected in series through socketing of corresponding axle holes; one surface of the connection disk facing the protection plate is provided with two elastic snaps corresponding to the two rectangle holes. The two elastic snaps of the connection disk are snapped in the steps. A liquid channel is formed from the cavity of the syringe to the forepart of the pacifier, and the outlet of the liquid channel is disposed at the flat surface of the forepart of the pacifier. | 2016-03-17 |
| 20160074288 | INTRAORAL FIXING COMPOSITION - An intraoral fixing composition, containing: titanium apatite, which is obtained by substituting part of calcium in calcium hydroxyapatite with titanium, wherein the intraoral fixing composition is fixed at an intraoral site in an unreleasable state. | 2016-03-17 |
| 20160074289 | THICKENING COMPOSITION - There is provided a thickening composition. A thickening composition including: an electrolyte; and cellulose fibers having an average fiber diameter of 0.001 to 100 μm and containing hemicellulose and amorphous regions. | 2016-03-17 |
| 20160074290 | Strip for the Delivery of an Oral Care Active and Methods for Applying Oral Care Actives - A strip of material for the delivery of an oral care active is disclosed. The strip of material includes a structural elastic-like film backing layer including a strainable network having a first region and a second region formed of substantially the same material composition, the first region providing a first, elastic-like resistive force to an applied axial elongation, and the second region providing a second distinctive resistive force to further applied axial elongation, thereby providing at least two stages of resistive forces in use; and an oral care composition disposed on the film, the oral care composition including an oral care active. | 2016-03-17 |
| 20160074291 | ANTI-AGING SKIN CARE COMPOSITIONS AND REGIMENS - Multi-step cosmetic regimens are provided to improve the appearance of aging skin. A target portion of skin that exhibits a sign of skin aging is identified. A first formulation is topically applied, comprising at least one active possessing an ability to transcriptionally up-regulate an eigengene derived from a genetic co-expression module for one or more biological themes associated with skin cleansing and/or skin detoxification, and/or skin hydration to the target portion of skin. A second formulation is also topically applied, comprising at least one active possessing an ability to transcriptionally up-regulate an eigengene derived from a co-expression module for one or more biological themes associated with skin repair and/or rebuilding to the target portion of skin. | 2016-03-17 |
| 20160074292 | MINERAL SALTS FOR REDUCING THE CONTENT OF CYSTEIC ACID IN KERATIN FIBRES - Cosmetic, non-therapeutic use of (a) sodium chloride in agents for oxidatively dyeing and/or oxidatively lightening keratinic fibers reduces the damage to the keratinic fibers resulting from use of the agents. Also, a ready-to-use agent for oxidatively dyeing and/or oxidatively lightening keratinic fibers includes (a) sodium chloride, (b) potassium chloride, (c) optionally at least one further salt from the group magnesium carbonate, magnesium hydrogen carbonate, magnesium sulfate, magnesium hydrogen sulfate, magnesium chloride, calcium carbonate, calcium hydrogen carbonate, calcium hydrogen sulfate, calcium sulfate, and/or calcium chloride, and (d) hydrogen peroxide. | 2016-03-17 |
| 20160074293 | Cosmetic Compositions and Methods for Inhibiting Melanin Synthesis - A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include bisabolol, undecylenoyl phenylalanine and/or hexyldecanol, and a material selected from the group consisting of ethyl palmitate, stearyl alcohol, bis(2-ethylhexyl)adipate, bis(2-ethylhexyl)maleate, 5-pentadecanol, 1-stearoyl-rac-glycerol, bis(2-ethylhexyl)sebacate, and mixtures thereof. A method of reducing the synthesis of melanin by using the cosmetic compositions is also disclosed herein. | 2016-03-17 |
| 20160074294 | Chemical Formulations and Their Use in Neutralizing or Eliminating Odors - The present invention is a chemical formulation and method of using the chemical formulation to neutralize or eliminate odors on a surface. In one aspect, the chemical formulation is an aqueous solution of multivalent citrate salts that may further comprise a surfactant, a fragrance and/or a coloring agent. The method comprises the steps of applying this formulation in sufficient volume to saturate the surface and, after the formulation has had time to react thereby neutralizing or eliminating the odor and absorbing or drying the formulation from the surface. In another aspect, the formulation of multivalent citrate salts may be applied in solid form to an odorous aqueous solution or may be used to coat an absorbent matrix for use in receiving an odorous aqueous solution. | 2016-03-17 |
| 20160074295 | METHOD FOR LIGHTENING SKIN WITH RICINOLEIC ACID - Skin lightening additives and skin lightening compositions having at least one of a heterosubstituted, saturated or unsaturated aliphatic acid are described. The compositions are suitable for topical application and comprise ricinoleic acid. | 2016-03-17 |
| 20160074296 | METHOD FOR STRAIGHTENING HUMAN HAIR FIBERS USING HEATING MEANS AND AN a-HYDROXY ACID DERIVATIVE - The invention concerns a method for straightening keratinous fibers including: (i) a step of applying on the keratinous fibers a hair straightening composition containing at least one alpha-hydroxy and/or keto acid derivative, the pH of said composition being not more than 9 (ii) a step of increasing the temperature of the keratinous fibers, using heating means, to a temperature ranging between 110 and 250° C. | 2016-03-17 |
| 20160074297 | COMBINATION OF PETROSELINIC ACID AND TAURINE FOR ORAL ADMINISTRATION FOR HAIR AGING CONTROL - The invention relates to the cosmetic use, by oral administration, of a combination of active agents including petroselinic acid and taurine, for improving hair quality and for preventing and controlling the microinflammation of hair follicles, in particular for controlling hair aging in men over the age of 30 or in women. | 2016-03-17 |
| 20160074298 | POLYPHENOL/FLAVONOID COMPOSITIONS AND METHODS OF FORMULATING ORAL HYGIENIC PRODUCTS - Microemulsions and soluble alkali metal salts of relatively insoluble aglycone polyphenols within oral hygienic products are disclosed for treating oral inflammatory disorders. The formulations can act as a bactericide or bacteriostat. The methods include the process associated with the formation of a high temperature polyphenol/surfactant concentrate, a nano-particulate precipitation process in the presence of a surfactant and the solubilization of relatively insoluble aglycone polyphenols/flavonoids by the formation of soluble alkali metal salts within alkaline oral compositions. Also disclosed are compositions that persist in the oral cavity, penetrate teeth, and facilitate or enhance the delivery of chemical elements and active ingredients to teeth for preventing or treating disorders and diseases of the oral cavity. Methods of use, and methods of making, the aforementioned compositions are also disclosed. | 2016-03-17 |
| 20160074299 | Producing Method Of Cosmetics Composition For A Lip Tattoo Pack And Therefrom - Disclosed is a cosmetic composition spread on lips to provide a color to lips. Disclosed are a lip pack cosmetic composition for tattooing and a method of preparing the same wherein lips are pigmented and thereby have tattoo effects by removing a formed layer after pigmenting a color on lips and drying the pigmented lips. | 2016-03-17 |
| 20160074300 | SOLID CONCENTRATE COMPOSITIONS CONTAINING ZINC PYRITHIONE - The present invention relates to a solid concentrate composition comprising: (a) from 5% to 25% by weight of zinc pyrithione (ZPT); (b) from 8% to 85% by weight of at least one surfactant, preferably, wherein the solid concentrate composition has a penetration hardness of between 20 N and 50 N according to the test method as disclosed herein. | 2016-03-17 |
| 20160074301 | ANTI-AGING SKIN CARE COMPOSITIONS AND REGIMENS - Multi-step cosmetic regimens are provided to improve the appearance of aging skin. A target portion of skin that exhibits a sign of skin aging is identified. A first formulation is topically applied, comprising at least one active possessing an ability to transcriptionally up-regulate an eigengene derived from a genetic co-expression module for one or more biological themes associated with skin cleansing and/or skin detoxification, and/or skin hydration to the target portion of skin. A second formulation is also topically applied, comprising at least one active possessing an ability to transcriptionally up-regulate an eigengene derived from a co-expression module for one or more biological themes associated with skin repair and/or rebuilding to the target portion of skin. | 2016-03-17 |
| 20160074302 | Skin Care Product and Method of Use - A cosmetic skin care product that includes an applicator and a skin care composition. The applicator includes a uni-directional magnetic array with a pitch of between 1.7 and 2.5 and a magnetic field strength of between about 24.0 and 36.0 mT. The skin care composition includes palmitoyl-lysine-threonine-threonine-lysine-serine and a dermatologically acceptable carrier. The magnetic array is tailored to enhance penetration of the Pal-KTTKS into skin during application of the skin care composition. The applicator may include a second magnetic array juxtaposed on a first magnetic array to form a bi-directional array that enhances penetration of the Pal-KTTKS into skin. | 2016-03-17 |
| 20160074303 | METHOD OF MAKING A SKIN CARE PRODUCT - A method of making a skin care product that includes a skin care composition containing a skin care active with a diamagnetic susceptibility of between about −400 and −600, constructing an applicator for applying the skin care composition to a target portion of skin, and packaging the composition and applicator for retail sale. The applicator includes a magnetic array tailored to enhance penetration of the skin care active into skin. The magnetic array may be unidirectional magnetic array or a bi-directional magnetic array. | 2016-03-17 |
| 20160074304 | GELLANT - The present invention provides a novel gellant capable of favorably gelatinizing an oily base. | 2016-03-17 |
| 20160074305 | VISCOUS COMPOSITION - A viscous composition of the present invention comprises specific cellulose fibers (A), (A′) and (A″) and the specific cellulose fibers (A), (A′) and (A″) are used with appropriate selection according to uses of a cosmetic composition, a gel-like composition and a spray composition. Therefore, in case where the composition is used as the cosmetic composition, a cosmetic composition which is excellent in shape retention ability and dispersion stability and excellent in water tolerance to satisfy the properties and the performance which is necessary for cosmetics is obtained. Additionally, in case where the composition is used as a gel-like composition, gel-state can be kept without separation or water release. Furthermore, in case where the composition is used as a spray composition, since it is possible to time-dependently keep stable gel state even if functional additives such as electrolytes, ionic substances, etc. are contained, it is possible to mix various functional additives which is necessary for the use without any problem. | 2016-03-17 |
| 20160074306 | VISCOUS COMPOSITION - A viscous composition of the present invention comprises specific cellulose fibers (A), (A′) and (A″) and the specific cellulose fibers (A), (A′) and (A″) are used with appropriate selection according to uses of a cosmetic composition, a gel-like composition and a spray composition. Therefore, in case where the composition is used as the cosmetic composition, a cosmetic composition which is excellent in shape retention ability and dispersion stability and excellent in water tolerance to satisfy the properties and the performance which is necessary for cosmetics is obtained. Additionally, in case where the composition is used as a gel-like composition, gel-state can be kept without separation or water release. Furthermore, in case where the composition is used as a spray composition, since it is possible to time-dependently keep stable gel state even if functional additives such as electrolytes, ionic substances, etc. are contained, it is possible to mix various functional additives which is necessary for the use without any problem. | 2016-03-17 |
| 20160074307 | THREADS OF HYALURONIC ACID AND/OR DERIVATIVES THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF - The present invention provides threads of hyaluronic acid, and/or derivatives thereof, methods of making thereof and uses thereof, for example, in aesthetic applications (e.g., dermal fillers), surgery (sutures), drug delivery, etc. | 2016-03-17 |
| 20160074308 | METHOD FOR PRODUCING A COSMETIC CLEANING AGENT - A method for producing a cosmetic cleaning agent includes: a) providing a preparation, which includes at least one acrylate homo-, co-, and/or crosspolymer in water, and heating and stirring the preparation at 30-40° C.; b) adding at least one antibacterial, antifungal, and/or antiseptic active substance, which is optionally dissolved, dispersed, or suspended in water and is selected from benzoic acid, salicylic acid, dehydroacetic acid, sorbic acid, cinnamic acid, and/or the physiologically acceptable salts of said acids, to the preparation from step a) and mixing the preparation from step a) with the at least one active substance; c) adding at least one surfactant, selected from anionic, amphoteric/zwitterionic, and/or nonionic surfactants, to the mixture from step b) and mixing the preparation from step b) with the at least one surfactant; d) optionally adding additional cosmetic active substances to the preparation from step c); and e) adding solid polylactic acid particles to the preparation from step c) or d). | 2016-03-17 |
| 20160074309 | COSMETIC SKIN-CARE AGENT - Cosmetic or dermatological topical compositions include, in a suitable cosmetic or dermatological carrier, a) polylactic acid particles and b) at least one active substance selected from monomers, oligomers, and polymers of amino acids, N—C | 2016-03-17 |
| 20160074310 | Composition Containing Oil Bodies, Fatty Acids, Amino Acid Surfactants And N-Methyl-N-Acylglucamines - The invention relates to compositions containing: (A) at least one N-acyl-amino acid surfactant as component A, (B) at least one N-methyl-N-acylglucamine as component B, (C) at least one C | 2016-03-17 |
| 20160074311 | Consumer Goods Product Comprising Chitin, Lignin and a Polymer or Co-Polymer - The present invention relates to a consumer good product comprising:
| 2016-03-17 |
| 20160074312 | EXTRACT OF PASSIONFLOWER SEEDS AND COSMETIC, PHARMACEUTICAL, DERMATOLOGICAL AND NUTRACEUTICAL COMPOSITIONS COMPRISING SAME - The invention relates to a composition comprising an extract of passionflower seeds, and preferentially | 2016-03-17 |
| 20160074313 | COMPOSITIONS COMPRISING ELAEAGNUS LANCELOTUS EXTRACT - Disclosed are compositions that include | 2016-03-17 |
| 20160074314 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS - Disclosed is a method of treating a skin condition, the method comprising topically applying to skin in need thereof a composition comprising an effective amount of an aqueous or alcoholic extract from the leaf of | 2016-03-17 |
| 20160074315 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF - Topical cosmetic compositions are provided that can comprise a | 2016-03-17 |
| 20160074316 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF - Topical cosmetic compositions are provided that can comprise a | 2016-03-17 |
| 20160074317 | ANTIOXIDANT EXTRACT FROM BROWN MACROALGAE AND METHOD FOR OBTAINING SAME - The invention relates to a method for obtaining antioxidant extracts from macroalgae using ultrasound-assisted continuous aqueous extraction. The process can be performed using fresh alga or dry alga, after resuspending same in water. A suspension of alga in water is prepared with a solid concentration of between 10 and 30%. The mixture is fed to an ultrasonic disruption system. The extract is filtered and lyophilized, obtaining total polyphenol concentrations of 62.4 mg eq. of phloroglucinol/g of lyophilisate with | 2016-03-17 |
| 20160074318 | Inhalable Pharmaceutical Compositions and the Inhaler Devices Containing Them - An inhalable pharmaceutical composition suitable for giving improved feedback to the patient about the inhalation of the metered doses in a range between 5 miligram and 10 miligram and suitable for use in a dry powder inhaler comprises 70 mass %-99.5 mass % of pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulation and 0.5 mass %-30 mass % of one or two pharmaceutically active ingredient(s). | 2016-03-17 |
| 20160074319 | TOPICAL COMPOSITION CONTAINING ANTIOXIDANTS - Disclosed herein are compositions for topical application that effectively deliver antioxidants across the epidermis, dermis, or a combination thereof into cells and/or the bloodstream while concurrently maintaining chemical activity of the antioxidants. In certain aspects, these formulations include emulsions and balms each having a lipophilic carrier and a lipophilic antioxidant solubilized by the lipophilic carrier. Also disclosed herein are methods for making these compositions for topical application. | 2016-03-17 |
| 20160074320 | PHARMACEUTICAL COMPOSTIONS COMPRISING KISSPEPTIN OR DERIVATIVES THEREOF - The present invention relates to pharmaceutical compositions comprising a peptide that stimulates the release of gonadotropins and sexual steroids. More specifically, the present invention provides pharmaceutical compositions comprising kisspeptin, preferably in the kp-10 form, or derivatives thereof, for use in ovulation cycle inducing and/or infertility treatment programs. The formulations according to the present invention belong to two main groups: injectable solutions and implantable formulations. The injectable solutions according to the present invention can be divided into immediate release solutions and prolonged action solutions. The implantable formulations according to the present invention can be prepared using an RTV silicone elastomer, a rapid vulcanization silicone elastomer or a rapid vulcanization silicone elastomer with a release modulator. | 2016-03-17 |
| 20160074321 | OPHTHALMIC COMPOSITION, METHOD FOR PREPARING THE SAME, AND USE OF THE SAME - The present invention is directed to an ophthalmic composition, method for preparing the same, and use of the same. The ophthalmic composition includes a mixture of lipid nano-dispersion and gel substrate, wherein the lipid nano-dispersion includes a first lipid, a second lipid, and emulsifier; in which the first lipid exists in form of solid lipid as staring material, and the second lipid exists in form of liquid lipid as staring material. The ophthalmic composition can better reduce the symptoms of dry eye, and is safe, convenient and economical to use, and can be used during daytime without blocking of vision. | 2016-03-17 |
| 20160074322 | ORAL CEFEPIME COMPOSITIONS AND USES THEREOF - The invention features pharmaceutical compositions, methods, and kits including cefepime, or a pharmaceutically acceptable salt thereof and an additive including an acyl carnitine. The additive is present in an amount sufficient to increase the oral bioavailability of the cefepime. | 2016-03-17 |
| 20160074323 | MICROCHIP SUBSTANCE DELIVERY DEVICES HAVING LOW-POWER ELECTROMECHANICAL RELEASE MECHANISMS - Electromechanical substance delivery devices are provided which implement low-power electromechanical release mechanisms for controlled delivery of substances such as drugs and medication. For example, an electromechanical device includes a substrate having a cavity formed in a surface of the substrate, a membrane disposed on the surface of the substrate covering an opening of the cavity, and a seal disposed between the membrane and the surface of the substrate. The seal surrounds the opening of the cavity, and the seal and membrane are configured to enclose the cavity and retain a substance within the cavity. An electrode structure is configured to locally heat a portion of the membrane in response to a control voltage applied to the electrode structure, and create a stress that causes a rupture in the locally heated portion of the membrane to release the substance from within the cavity. | 2016-03-17 |
| 20160074324 | SLOW AND CONTROLLED RELEASED LIPOSOMAL GEL COMPOSITION COMPRISING HYPOGLYCEMIC ACTIVE INGREDIENT AND METHOD OF PREPARING THEREOF - The present invention provides a slow and controlled released liposomal gel composition for subcutaneous administration comprises insulin or exenatide as active ingredient for reduction of blood sugar level and method of preparation thereof. Said controlled released composition has high bioavailability and is demonstrated to be able to sustain release therapeutically effective concentration of drug over a period of time and without rapid release of drug after initial administration. Method of preparing the controlled released composition of the present invention comprises the following steps: mixing insulin or exenatide, lipid and aqueous dispersion medium together; then mixing with poloxamer (e.g. F127 or P123) and/or gelatin and hyaluronic acid (HA) or the like gel solution so as to form a protective layer on surface of every lipid micro vesicles or nano-vesicles for use in intramuscular, abdominal and subcutaneous administration. A single administration of the present composition lasts 2 to 7 days to reduce side-effects, such as pain and irritation. | 2016-03-17 |
| 20160074325 | Low-Dimensional Structures of Organic and/or Inorganic Substances and Use Thereof - The object of the present invention is low-dimensional, primarily 2D folded structures of organic and/or inorganic substances and/or their agglomerates, which have folds and faces of irregular shape and exhibit high local electric field strength generated by surface charges on the said folds, faces and edges, and use thereof: as sorbents of organic particles (molecules, bacteria, viruses, proteins, antigens, endotoxins) and inorganic particles (metal ions, colloids); as an agent with wound healing and antibacterial activity; as an agent for tumor cell growth inhibition. | 2016-03-17 |
| 20160074327 | PROCESS FOR PREPARING MICROPARTICLES - A process for preparing microparticles comprising a biologically active material and a polymer and having a mean particle size expressed as the volume mean diameter (VMD) of from 10 to 500 μm, wherein the biologically active material is substantially insoluble in the polymer, which process comprises: a. contacting a mixture of the biologically active material or a precursor thereof, the polymer or a precursor thereof and a processing aid with a supercritical fluid which is capable of swelling the polymer under temperature and pressure conditions necessary to maintain the fluid in a supercritical state; b. allowing the supercritical fluid to penetrate and liquefy the polymer, whilst maintaining the temperature and pressure conditions so that the fluid is maintained in a supercritical state; c. releasing the pressure to precipitate microparticles comprising the biologically active agent and the polymer. | 2016-03-17 |
| 20160074328 | Drug Particles From Freezing Onto A Surface - The present invention is a method for preparing micron-sized or submicron-sized drug particles comprising contacting a solution comprising a poorly water soluble drug substance and at least one freezable organic solvent with a cold surface so as to freeze the solution; and removing the organic solvent. The resulting particles are also disclosed, as are several embodiments of an apparatus that can be used in performing the method of the present invention. | 2016-03-17 |
| 20160074329 | RATE MODULATED DELIVERY OF DRUGS FROM A COMPOSITE DELIVERY SYSTEM - This invention relates to a pharmaceutical dosage form for the delivery of at least one active pharmaceutical ingredient (API) or the pharmaceutically active salts and isomers thereof, to a desired absorpion location of the human or animal body, preferably the gastrointestinal tract, in predetermined rate-modulated manner. The dosage form is orally ingestible and is in the form of a multi-layered tablet or capsule containing a multiplicity of multi-layered granules. Each layer contains one or more APIs mixed or blended with at least one and preferably a matrix of polymers and, where appropriate, excipients, which, in use, inhibit release of an API in a region of the gastrointestinal tract other than the desired absorption location and, thus, facilitate release of the API in a rate controlled manner when in that desired absorption location. | 2016-03-17 |
| 20160074330 | SOLID PHARMACEUTICAL COMPOSITION - [Problem] To provide a novel pharmaceutical composition which contains a medically active component and which can suppress delays in the release of said component due to gelling. | 2016-03-17 |
| 20160074331 | COMPOSITE STRUCTURAL MATERIAL AND PHARMACEUTICAL COMPOSITION THEREOF - A composite structural material and pharmaceutical composition comprising same, the use of the composite structural material in preparing a sustained release formulation, and a pharmaceutical composition formulation method; the composite structural material comprises a hydrophobic structural material and a hydrophilic structural material; the proportion of the hydrophobic structural material to the hydrophilic structural material ranges from 1:0.01 to 1:5, preferably 1:0.05 to 1:4, more preferably 1:0.1 to 1:3, and most preferably 1:0.4 to 1:2, such as 1:0.4 to 1:1.3. The pharmaceutical composition comprises the composite structural material and one or more active pharmaceutical ingredients, and preferably the proportion of the composite structural material to the active pharmaceutical ingredients ranges from 1:0.01 to 1:8, more preferably 1:0.02 to 1:5, and most preferably 1:0.03 to 1:1, such as 1:0.3 to 1:0.7. | 2016-03-17 |
| 20160074333 | Pharmaceutical compositions of tamsulosin or salts thereof - The present invention relates to pharmaceutical compositions of tamsulosin or salts thereof. In particular, the invention relates to pharmaceutical compositions comprising a core of tamsulosin or salts, hydrates thereof and at least one specialized coating over the core. Such compositions of tamsulosin may exhibit desired release kinetics with excellent storage stability and particularly, levels of degradants in the formulation during storage can be effectively controlled. The invention also includes a process of preparing such compositions and additionally combination with other pharmaceutical ingredient. | 2016-03-17 |
| 20160074334 | Differential Tumor Cell Cytotoxicity Via Contact With Coated Cerium Oxide Nanoparticles - Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines. In contrast, minimal toxicity is observed when they localize into the cytoplasm or do not enter the cells. | 2016-03-17 |
| 20160074335 | FIBER/GRANULE COMPLEX FOR TREATMENT OF THE GI TRACT - A method for treating a gastrointestinal (GI) tract including providing a fiber/granule complex made of non-absorbable fibers having granules attached thereto, and ingesting the fiber/granule complex orally, wherein the fiber/granule complex treats materials in the GI tract as it passes through the GI tract, the fiber/granule complex not being substantially absorbed by the GI tract. | 2016-03-17 |
| 20160074336 | Transdermal Therapeutic System Comprising an Adhesive Layer Method for Siliconizing the Back Layer of the System and Use of Said Back Layer - The invention generally relates to a transdermal therapeutic system which comprises a backing layer, an adhesive layer, a polymer layer and a removable protective layer. The adhesive layer is an organosiloxane layer that is anchored to the backing layer by siliconization. | 2016-03-17 |
| 20160074337 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL - The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to substituted hexitols such as dibromodulcitol or analogs, derivatives, or prodrugs thereof. | 2016-03-17 |
| 20160074338 | FOOD COMPOSITION FOR PREVENTING OBESITY, PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY, AND ANIMAL MEDICINE FOR TREATING OBESITY, CONTAINING GINGERNONE A - Disclosed is a composition comprising gingerenone A as an active ingredient. The composition includes a food composition for preventing obesity, a pharmaceutical composition for treating obesity and a medicine for treating animal obesity. Since the composition includes gingerenone A, which inhibits expression of the important transcriptional factors C/EBPα and PPARγ, expressed upon adipocyte differentiation, as well as FAS protein expression, the composition has superior potential for obesity prevention or treatment. | 2016-03-17 |
| 20160074339 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING ELCTROPHILE-MEDIATED TOXICITIES - Methods and compositions using 1,3-dicarbonyl compounds are disclosed for treating toxicity due to therapeutic agents and agents that causes oxidative cellular damage and for treating liver ischemia-reperfusion injury, as well as diseases and disorders that are improved through administration of N-acetylcysteine. | 2016-03-17 |
| 20160074340 | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION - The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations) comprising genotyping a patient to determine their Val66Met rs6265 polymorphism in BDNF and administering a ketamine, preferably esketamine, preferably intranasal esketamine, according to a dosing regimen matched to the patient's genotype. | 2016-03-17 |
| 20160074341 | Methods for Overcoming Resistance to Tramadol - There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients. | 2016-03-17 |
| 20160074342 | Titration of Tapentadol - The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a| 2016-03-17 | |
| 20160074343 | ENERGY DRINKS AND OTHER NUTRITIONAL AIDS DERIVED FROM AGAVE-BASED SPIRITS - Compositions containing monoamine oxidase inhibitors prepared by removal of alcohol from agave-derived beverages are disclosed. | 2016-03-17 |
| 20160074344 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY - This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected. | 2016-03-17 |
| 20160074345 | Composition for Prevention and Treatment of Contact Lens Papillary Conjunctivitis and Allergic Eye Disease - The invention provides a use of panthenol or dexpanthenol in the prevention and/or treatment of contact lens papillary conjunctivitis in a subject. A contact lens care solution containing 0.001 to 10% by dry weight dexpanthenol is also provided. | 2016-03-17 |
| 20160074346 | METHOD OF VIRAL INHIBITION - This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV. | 2016-03-17 |
| 20160074347 | Processes For The Preparation Of 2,5-Dihydroxybenzenesulfonic Acid Salts - Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5-dihydroxybenzenesulfonic acid are provided. Also provided are methods of treating rosacea comprising administering crystalline forms of potassium 2,5-dihydroxybenzenesulfonic acid. | 2016-03-17 |
| 20160074348 | Nutritional Intervention for Improving Muscular Function and Strength - The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality. | 2016-03-17 |
| 20160074349 | EPILEPSY TREATMENT EMPLOYING KETOGENIC COMPOUNDS WHICH ARREST APOPTOSIS - A method is provided for treating a patient suffering from apoptosis of tissue comprising administering to that subject a therapeutically effective amount of one or more ketogenic compounds such that a physiological ketosis is produced sufficient to arrest said apoptosis. Preferably the apoptosis is of cerebral tissue such as that associated with acute intractible seizures, particularly with status epilepticus. | 2016-03-17 |
| 20160074350 | Retinopathy Treatment - A method of preventing degeneration of photoreceptor cells in an eye of a mammalian subject includes the step of administering pharmaceutical composition comprising a sulindac agent to the eye of the subject. | 2016-03-17 |
| 20160074351 | DISPENSING SYSTEM - The invention provides systems and methods for controlled dispensing of topical analgesics contained in a metered dispensing system. The systems and method are useful for treating signs and symptoms of osteoarthritis. The method includes depressing a hand pump to dispense a dose of a topical pain reliever in a viscous solution from the hand pump, wherein the hand pump is configured to dispense the dose within a tolerance specified by a corresponding label approved by a government regulatory agency; and spreading the topical solution on skin. | 2016-03-17 |
| 20160074352 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2016-03-17 |
| 20160074353 | USE OF PETROSELINIC ACID TO FIGHT AGAINST AESTHETIC DISORDERS OF THE BODY FIGURE - The present invention concerns the cosmetic use, by oral administration, of petroselinic acid or of a combination of active ingredients comprising at least petroselinic acid and at least one compound chosen from zinc, taurine, one of the salts of same, lycopene and the mixtures thereof, and preferably at least taurine or zinc gluconate and, more preferably still, at least taurine and zinc gluconate, with the aim of fighting against aesthetic disorders of the body figure linked to modifications in the adipose tissue. | 2016-03-17 |
| 20160074354 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF - The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods. | 2016-03-17 |
| 20160074355 | Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters - Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided. | 2016-03-17 |
| 20160074356 | METHODS OF TREATING UREA CYCLE DISORDERS - The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age. | 2016-03-17 |
| 20160074357 | TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING - The present invention relates to the use of tetrahydrocannabivarin (THCV) in the treatment of nausea and vomiting. Preferably the THCV is isolated and/or purified from cannabis plant extracts. Preferably the nausea and/or vomiting is caused by the effects of a medication such as a chemotherapeutic agent. | 2016-03-17 |
| 20160074358 | PPAR alpha/gamma Dual Agonist and Its Application - The present invention discloses a PPAR α/γ dual agonist and its application. The PPAR α/γ dual agonist comprises an effective amount of the compounds represented by formula I or/and its pharmaceutically acceptable derivative. Wherein. R | 2016-03-17 |
| 20160074359 | METHODS OF STIMULATING CELLULAR GROWTH, SYNAPTIC REMODELING AND CONSOLIDATION OF LONG-TERM MEMORY - The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC. | 2016-03-17 |
| 20160074360 | COMBINED DRUG ADMINISTRATION OF DALCETRAPIB AND ORLISTAT - The present invention is directed to the combined administration of a thioester therapeutic agent (preferably of formula I) and at least one esterase inhibitor. Also provided are a pharmaceutical composition, package, and a kit comprising the aforementioned active ingredients, as well as a method for increasing the bioavailability of said thioester for the treatment and prophylaxis of a cardiovascular disorder. | 2016-03-17 |
| 20160074361 | PRO-NEUROGENIC COMPOUNDS - This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like. | 2016-03-17 |
| 20160074362 | PHARMACEUTICAL AGENT - Provided is a composition for use in treating a skin condition, the composition comprising:
| 2016-03-17 |
| 20160074363 | METHODS FOR IMPROVING LIPID PROFILES USING ATRASENTAN - The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol. | 2016-03-17 |
| 20160074364 | PYRAZOLE-AMIDE COMPOUNDS AND PHARMACEUTICAL USE THEREOF - A compound represented by the following formula: | 2016-03-17 |
| 20160074365 | Histidine and/or Histidine Derivative for the Treatment of Inflammatory Skin Diseases - Histidine and/or a derivative thereof. In some embodiments, the histidine and/or a derivative thereof is used in maintaining and/or improving barrier function of the skin of a subject. In some embodiments, the histidine and/or a derivative thereof is used for the prevention and/or treatment of an inflammatory skin disease. | 2016-03-17 |
| 20160074366 | TREATMENT USING DANTROLENE - Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease. | 2016-03-17 |
| 20160074367 | AMYLOID PRECURSOR PROTEIN MRNA BLOCKERS FOR TREATING DOWN SYDNROME AND ALZHEIMER'S DISEASE - The present disclosure relates to methods for treating a neurodegenerative disorder by administering an effective amount of an agent that inhibits or reduces translation of amyloid precursor protein. In some embodiments, the neurodegenerative disorder is Alzheimer's disease or Down syndrome. Also disclosed are methods for decreasing amyloid-beta production in a subject's brain. Further disclosed is a method for restoring or maintaining iron homeostasis in a subject's brain. | 2016-03-17 |
| 20160074368 | VELIPARIB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN SMOKERS - This invention pertains to a method for the treatment of non-small cell lung cancer in a subject who is a smoker, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (veliparib or ABT-888), or a pharmaceutically acceptable salt thereof, in combination with carboplatin and paclitaxel. | 2016-03-17 |
| 20160074369 | BIOTIN FOR USE IN TREATING X-LINKED ADRENOLEUKODYSTROPHY - The invention relates to the use of biotin for treating X-linked adrenoleukodistrophy, in particular adrenomyeloneuropathy. | 2016-03-17 |
| 20160074370 | METHODS OF INHIBITING CATARACTS AND PRESBYOPIA - Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a γ-crystallin charge masking agent. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins. | 2016-03-17 |
| 20160074371 | Ocular Formulations for Drug-Delivery and Protection of the Anterior Segment of the Eye - The present application relates to topical formulations comprising Compound-I | 2016-03-17 |
| 20160074372 | METHODS AND COMPOSITIONS FOR ATTENUATING EXON SKIPPING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES - Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants. | 2016-03-17 |
| 20160074373 | METHODS AND COMPOSITIONS FOR INHIBITING HUMAN COPPER TRAFFICKING PROTEINS ATOX1 AND CCS - Compositions and methods concern organic molecules that bind to human Atox1 and CCS at the copper trafficking interface of these proteins. This binding suppresses copper trafficking, which leads to inhibition of cancer cell proliferation and tumor growth. In addition to serving as an effective treatment of cancer, these organic molecules inhibit cellular copper uptake and can be used as treatment of disorders of copper metabolism such as Wilson's disease, which is characterized by copper overload, as well as wound healing. | 2016-03-17 |
| 20160074374 | CORRECTORS ACTING THROUGH MSD1 OF CFTR PROTEIN - The present disclosure provides methods for treating Cystic Fibrosis in a subject by administering to the subject a corrector agent capable of acting through MSD1 during the biosynthesis of CFTR protein. The disclosure also provides methods of screening for new corrector agents capable of acting through MSD1 during the biosynthesis of a CFTR protein. | 2016-03-17 |
| 20160074375 | PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved. | 2016-03-17 |
| 20160074376 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS - The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. | 2016-03-17 |
| 20160074377 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS - The invention provides a chemical entity of Formula (I) | 2016-03-17 |
| 20160074378 | LAQUINIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS WITH A HIGH DISABILITY STATUS - This invention provides a method for treating or for reducing ambulatory deterioration in a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and having a high baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS), comprising periodically administering to only the patient diagnosed with RRMS and having a high baseline disability score an amount of laquinimod effective to treat the patient or to reduce ambulatory deterioration. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a human patient diagnosed to be afflicted with RRMS and having a high baseline disability score according to the EDSS. | 2016-03-17 |
